- Conditions
- Brain Metastases, Adult
- Interventions
- Patritumab deruxtecan
- Drug
- Lead sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Newly Diagnosed Glioblastoma, Recurrent Glioblastoma
- Interventions
- hEGFRvIII-CD3 (BRiTE)
- Drug
- Lead sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme
- Interventions
- Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 111In-labeled DCs, Temozolomide, Saline, Basiliximab
- Biological · Drug
- Lead sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma
- Interventions
- Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td), GM-CSF, 111-Indium-labeling of Cells for in vivo Trafficking Studies
- Biological · Drug
- Lead sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioma, Malignant
- Interventions
- Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine, Hiltonol
- Biological · Drug
- Lead sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina